Fixed dose combinations of empagliflozin and linagliptin for 52 weeks in drug-naive subjects with type 2 diabetes

被引：0
|
作者：
Lewin, A. [1 ]
DeFronzo, R. [2 ]
Patel, S. [3 ]
Liu, D. [4 ]
Kaste, R. [4 ]
Woerle, H. J. [5 ]
Broedl, U. C. [5 ]
机构：
[1] Natl Res Inst, Los Angeles, CA USA
[2] Univ Texas Hlth Sci, San Antonio, TX USA
[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[4] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
851
引用
收藏
页码：S346 / S347
页数：2
相关论文
共 50 条
  • [1] Combinations of empagliflozin/linagliptin for 24 weeks in drug-naive subjects with Type 2 diabetes
    Lewin, A.
    DeFronzo, R. A.
    Patel, S.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 90 - 90
  • [2] Safety and tolerability of combinations of empagliflozin/linagliptin for 52 weeks in subjects with type 2 diabetes
    Kohler, S.
    Patel, S.
    DeFronzo, R. A.
    Lewin, A.
    Liu, D.
    Kaste, R.
    Woerle, H. -J.
    Broedl, U.
    DIABETOLOGIA, 2015, 58 : S363 - S363
  • [3] Fixed dose combinations of empaglilozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes
    Patel, S.
    DeFronzo, R.
    Lewin, A.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S7 - S7
  • [4] Combinations of empagliflozin/linagliptin for 24 weeks as add-on to metformin in subjects with Type 2 diabetes
    Defronzo, R. A.
    Lewin, A.
    Patel, S.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 90 - 90
  • [5] Safety and Tolerability of Combinations of Empagliflozin/Linagliptin (EMPA/LINA) for 52 Weeks in Subjects with Type 2 Diabetes (T2DM)
    Patel, Sanjay
    Defronzo, Ralph A.
    Lewin, Andrew
    Liu, Dacheng
    Kaste, Renee
    Kohler, Sven
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A326 - A327
  • [6] Empagliflozin monotherapy in drug-naive patients with Type 2 diabetes
    Roden, M.
    Weng, J.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Stella, P.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [7] Efficacy and safety of linagliptin/metformin fixed-dose combination as initial therapy in drug-naive Asian patients with type 2 diabetes
    Gong, Y.
    Mu, Y.
    Fan, B.
    Hehnke, U.
    Pan, C.
    DIABETOLOGIA, 2015, 58 : S388 - S388
  • [8] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A69 - A69
  • [9] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael W.
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [10] Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
    Lewin, Andrew
    DeFronzo, Ralph A.
    Patel, Sanjay
    Liu, Dacheng
    Kaste, Renee
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES CARE, 2015, 38 (03) : 394 - 402
12345